dilatation of volume. Acute dilatation of stomach
Conditions
Interventions
Intervention 1: Intervention group: Metoclopramide, manufactured by Caspian Tamin Pharmaceutical Company, at a dose of 20 mg / 100 ml of normal saline, intravenously and one time. Intervention 2: Inte
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age between 20 and 60 years tube Patients under mechanical ventilation Patients with enteral nutrition through nasogastric
Exclusion criteria
Exclusion criteria: Previous use of beta-blockers Heart Block Bradycardia heart rate less than 60)before inclusion Hypothermia in the form of central temperature below 35 degrees Kidney Failure (CR> 1.5) Extra Recent surgery on stomach or digestive tract within the last ten days Signs and symptoms of bowel obstruction Pregnancy and lactation Active Sensitivity to Neostigmine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastric residual volume. Timepoint: Before starting the drug infusion and 3, 6, 9 and 12 hours after the start of the infusion. Method of measurement: Aspirate with a gavage syringe. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Moshari
Shahid Beheshti University of Medical Sciences
Outcome results
None listed